Innovotech Announces New Senior Management
17 January 2014 - 10:00PM
Marketwired
Innovotech Announces New Senior Management
EDMONTON, ALBERTA--(Marketwired - Jan 17, 2014) - Innovotech
Inc. (TSX-VENTURE:IOT), an innovator focused on providing new and
practical solutions to medical, agricultural and industrial
problems caused by microbial biofilms, today announced the
appointment of Dr. Amin Omar to the new position of General
Manager. Mr. Ken Boutilier has stepped down as President and CEO of
Innovotech, effective January 1, 2014 and Dr. James Timourian has
been appointed to the position of President. Mr. Bruce Hirsche will
continue as Secretary and Dr. James Timourian will continue as
Chairman of the Board.
"Dr. Amin Omar, with Innovotech since 2007, has been responsible
for building Innovotech's outstanding reputation of scientific and
regulatory expertise in the field of infection control. We have
confidence that the management team we now have in place will
successfully lead Innovotech through the coming phases of its
development. The Company will continue to focus on expanding its
revenue services and developing significant markets for its most
promising technologies," said Dr. James Timourian, Chairman of the
Board. "We greatly appreciate Ken's service to Innovotech and wish
him good fortune in his future endeavors."
About Innovotech
Inc:
Innovotech Inc. is an innovator in the field of biofilm
product development, focused on providing innovative and practical
solutions to medical, agricultural and industrial problems
caused by microbial biofilms. Biofilms are
organized communities of microorganisms that exist in virtually
every natural environment and are responsible for a host of
diseases in human health, animal health and agriculture. There are
few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming
organisms.
Innovotech has a range of products that address the issue of
biofilms within a number of different industries, including
commercially available products in a variety of market segments;
the MBEC Assay™, InnovoSIL™, bioFILM PA™, InnovoSCEPT™-Human and
InnovoSCEPT™-Veterinary tests. The MBEC Assay™ is a high throughput
biofilm growth device that is an ASTM International standard.
InnovoSIL™ is a family of silver-based antimicrobials promising
superior performance for medical device coatings and wound
dressings, bioFILM PA™ and InnovoSCEPT™-Human are the first
diagnostic tests to assist physicians in the selection of the most
effective antibiotic treatment for patients with biofilm-based
chronic infections, while the InnovoSCEPT™-Veterinary
tests are designed to determine the most effective antibiotic
treatment for chronic infections in both large and small
animals
This document may contain forward-looking statements that
are predictive in nature and subject to risks and uncertainties
that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed
or implied by any forward-looking statements. Factors that could
cause or contribute to such risks or uncertainties include, but are
not limited to: the regulatory environment including the difficulty
of predicting regulatory outcomes; changes in the value of the
Canadian dollar; the Company's reliance on a small number of
customers including government organizations; fluctuations in
operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships;
uncertainty related to intellectual property protection and
potential costs associated with its defense; the Company's exposure
to lawsuits and other matters beyond the control of management.
Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company
undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable
law.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Innovotech Inc.Dr. James TimourianPresident780.448.0585 ext
221james.timourian@innovotech.cawww.innovotech.ca
Innovotech (TSXV:IOT)
Historical Stock Chart
From May 2024 to Jun 2024
Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2023 to Jun 2024
